|
|
Post by selluwud on Dec 19, 2015 13:08:46 GMT
|
|
|
|
Post by selluwud on Dec 20, 2015 14:05:20 GMT
|
|
|
|
Post by jckrdu on Dec 20, 2015 15:20:56 GMT
This doesn't bother me. Athersys has had a line open with Aspire for many years. This latest renewal for 16M shares (20% dilution) is for a 3 year period, and would take the share count from 83M to 100M when its all used, hopefully 3 years from now.
Will we see another offering sometime in the next 3 years? That's certainly possible, but I'm not sure. IMO, this line with Aspire reduces the likelihood of another offering, as ATHX has a good cash position and has moved their programs forward using grants to fund a large chunk of the costs in the past. My hope is that the upcoming partnership announcement for stroke (and other indications) in Japan comes with a decent amount of upfront cash with the partner funding 100% of the trial costs. I'm also looking for another partnership for stroke (and other indications) to be announced in 2016 for Europe and the US.
Combined with the $30M line from Aspire, the upfront cash from both of those pending partnerships should be enough to keep ATHX well funded for the foreseeable future.
|
|
